Dec 28, 2025 • MarketBeat
NEUTRAL
BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd.
TB Alternative Assets Ltd. significantly reduced its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 92.7% in Q3 2025, selling over 26,000 shares. Despite this sell-off, several major institutional investors, including Dodge & Cox, BNP Paribas, and Bank of New York Mellon Corp, either initiated or substantially increased their positions in BioNTech, indicating strong buyer interest. BioNTech recently missed its Q3 EPS estimates but exceeded revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $137.75.
Dec 27, 2025 • AD HOC NEWS
SOMEWHAT-BULLISH
CureVac Shareholders Approve Final Chapter with BioNTech Acquisition
CureVac's acquisition by BioNTech SE has been finalized, ending CureVac's independent trading journey after 25 years. The deal, supported by 86.75% of CureVac shareholders, makes BioNTech CEO Ugur Sahin the new head, with plans for strategic and scientific integration. CureVac shares are set for compulsory acquisition and delisting in January 2026.
Dec 26, 2025 • TipRanks
BEARISH
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know
The early termination of Genmab and BioNTech's Phase 1/2 clinical trial for their cancer antibody, GEN1055, in solid tumors has been announced, signaling a setback for the program. While the exact reasons for termination are not specified, it could be related to safety or efficacy, impacting near-term investor enthusiasm for both companies. However, the diversified pipelines of Genmab and BioNTech are expected to limit long-term damage, with attention shifting to their other oncology programs.
Dec 26, 2025 • AD HOC NEWS
SOMEWHAT-BULLISH
A New Chapter Begins: BioNTech Completes CureVac Acquisition
BioNTech SE has finalized its acquisition of CureVac N.V., marking a significant consolidation in the mRNA biotechnology landscape. The deal was structured as a share-for-share exchange, with BioNTech acquiring approximately 86.75% of CureVac's outstanding shares. This acquisition aims to deepen BioNTech's mRNA platform, broaden its applications, and integrate CureVac's assets into its pipeline, particularly in oncology and infectious disease applications.
Dec 26, 2025 • MarketBeat
SOMEWHAT-BULLISH
Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX
Vontobel Holding Ltd. has increased its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 17.9% in the third quarter, acquiring an additional 10,924 shares to now hold 72,096 shares valued at approximately $7.11 million. Analysts maintain a "Moderate Buy" consensus rating for BioNTech, with an average price target of $137.75. The company recently reported Q3 EPS of ($0.14) against an expected $0.75, but revenue surpassed estimates at $1.78 billion.
Dec 25, 2025 • AD HOC NEWS
BULLISH
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalized
BioNTech has officially completed its acquisition of CureVac N.V., a significant strategic expansion aimed at strengthening its mRNA platform and research capabilities. Despite some institutional selling, BioNTech's stock showed resilience, trading around $95, with Wall Street analysts placing an average price target of $139, suggesting a potential upside of over 46%. The company's focus now shifts to operationalizing synergies and integrating CureVac's assets to achieve these ambitious targets.